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Background: Several reports have shown that in patient with ST-segment elevation acute myocardial infarc-
tion (STEMI) longer ischemia time is associated with impaired reperfusion and higher mortality. However,
there is still some doubts with regards time to reperfusion role in patients treated with primary percutaneous
coronary intervention (PCI). Therefore, the aim of the current study was to evaluate the impact of time-to-
treatment on infarct size as evaluated by myocardial scintigraphy in a large cohort of STEMI patients under-
going primary PCI.
Methods: Our population is represented by 830 STEMI patients undergoing primary PCI. Infarct size was eval-
uated at 30 days by technetium-99m-sestamibi.
Results: Time-to-treatment was significantly associated with age and dyslipidemia. Time-to-treatment linearly
affected the rate of postprocedural TIMI 3 flow (pb0.0001) and scintigraphic infarct size (pb0.001). The impact
of time-to-treatment on infarct size persisted in the analysis restricted to patients with postpocedural TIMI 3
flow, and after correction for confounding factors such as age, dyslipidemia, postprocedural TIMI 3 flow (OR
[95% CI]=1.26 [1.14–1.39], pb0.001).
Conclusions: This study shows in a large population of STEMI patients undergoing primary PCI that time-to-
treatment is linearly associated with infarct size.© 2012 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Availability of pharmacologic and mechanical reperfusion thera-
pies has significantly reduced cardiac mortality among ST-segment
elevation acute myocardial infarction (STEMI) patients [1–11]. How-
ever, even though primary angioplasty has been shown to be superior
to thrombolysis, mainly due to a larger success in epicardial recanali-
zation, a suboptimal myocardial reperfusion is observed in a still rel-
evant percentage of patients [12,13]. A clear relationship between
mortality and time delay from symptom-onset to treatment has
been demonstrated in patients with STEMI treated by thrombolysis
[14,15]. Some studies have suggested a prognostic impact of time-
to-treatment in STEMI patients undergoing primary angioplasty
[16–21]. However, few data have been reported in terms of infarct
size. Moreover, myocardial perfusion scintigraphy has been widely
used to accurately assess infarct size in clinical trials and in current
medical practice. Therefore, the aim of the current study was to eval-
uate the influence of symptom-onset-to-balloon time on infarct size
as evaluated by technetium-99m-sestamibi in a large cohort of
patients with STEMI treated by primary angioplasty.: +39 0321 3733407.
Luca).
Ltd. All rights reserved.
ime-to-treatment and infarct2. Materials and methods
Our population is represented by 830 STEMI patients treated by primary angio-
plasty undergoing evaluation of infarct size at 30 days after the intervention. All pa-
tients were admitted within 12 h from symptom onset. All patients received aspirin
(500 mg intravenously), heparin (60 IU/kg IV) (both administrated out-of-hospital if
patients were transported by an ambulance otherwise at hospital admission after diag-
nosis) and clopidogrel (at hospital admission after diagnosis). The decision to provide
Gp IIb–IIIa inhibitors was left at the discretion of the operator in the cath lab. All pa-
tients were on dual oral antiplatelet therapy (aspirin and clopidogrel or ticlopidine)
for at least 4 weeks after stent implantation. Ischemia time was defined as the interval
between symptoms onset to first balloon inflation. The authors of this manuscript have
certified that they comply with the Principles of Ethical Publishing in the International
Journal of Cardiology [49].
2.1. Coronary angiography and mechanical revascularization
Selective coronary angiography was performed in multiple projections before me-
chanical reperfusion. Immediately after diagnostic angiography, angioplasty with ste-
nting of the infarct-related vessel was performed using standard material. Successful
primary percutaneous coronary intervention was defined as Thrombolysis In Myocar-
dial Infarction (TIMI) grade 3 coronary flow in the treated vessel with a residual steno-
sis b20% [22].
2.2. Infarct size assessment
As previously described [23], gated single-photon emission computed tomography
(SPECT) acquisition began 60 min after technetium-99m-sestamibi injection (740 MBq),
using a double-head gamma-camera equipped with high-resolution collimators, 180°size in STEMI patients undergoing primary angioplasty, Int J Cardiol
2 G. De Luca et al. / International Journal of Cardiology xxx (2012) xxx–xxxrotation arc, 32 projections, 60 s/projection, 8 frames/heart cycle and 64×64matrices.
The studies were reconstructed using filtered back-projection without attenuation or
scatter correction and realigned along the heart axis. Perfusion defects were quantified
as percentage of LV wall, with the defect threshold set at 60% of peak uptake [24].
2.3. Statistical analysis
Statistical analysis was performed with the SPSS 15.0 statistical package. Continu-
ous data were expressed as mean±SD and categorical data as percentage. The ANOVA
test was appropriately used for continuous variables. The chi-square test or the Fisher's
exact test was used for categorical variables. Patients were divided according to ische-
mia time (b2 h, 2–3 h, 3–4 h, 4–5 h, 5–6 h, and≥6 h). Multiple logistic regression anal-
ysis was used to evaluate the impact of ischemia time on infarct size after adjustment
for significant (pb0.05) confounding baseline characteristics.
3. Results
Patients characteristics are shown in Tables 1 and 2. Time-to-
treatment was significantly associated with age (pb0.001) and dys-
lipidemia (pb0.001). No differences were observed in terms of
other clinical characteristics. Time-to-treatment inversely affected
the rate of postprocedural TIMI 3 flow (pb0.0001) (Adjusted OR
[95% CI]=0.69 [0.59–0.81], pb0.001).
As shown in Fig. 1, time-to-treatment was linearly related to
infarct size. Similar results were observed when infarct size was di-
chotomized according to the median value (OR [95% CI]=1.25
[1.13–1.37], pb0.001) (Fig. 2). These data were confirmed even in
the analysis restricted to patients with postprocedural TIMI 3 flow
(Figs. 1B and 2B) and after the exclusion of patients with previous
MI (n=34). Fig. 3 shows the impact of ischemia time as continuous
function on infarct size (R2=0.0.14, beta=0.015, pb0.001). Identical
results were found after the exclusion of patients with previous MI
(R2=0.0.14, beta=0.015, pb0.001). Therefore, infarct size increased
by 0.9% per each hour delay to treatment. Subanalyses conducted
according to a threshold of ischemia time of 3 h did not show any het-
erogeneity in any of the analyzed subgroups according to age, sex,
diabetes, preprocedural TIMI flow, anterior infarct location and multi-
vessel disease (Fig. 4). By multiple regression analysis, time-to-
treatment significantly affected infarct size even after correction for
clinical (age and dyslipidemia) and procedural (postprocedural TIMI
3 flow) characteristics (OR [95% CI]=1.26 [1.14–1.39], pb0.001).
4. Discussion
This is one of the largest study conducted so far evaluating the im-
pact of time-to-treatment on scintigraphic infarct size in STEMI pa-
tients undergoing primary PCI. We found that time-to-treatment
was linearly and independently associated with infarct size.
Primary angioplasty has been shown to provide mortality benefits
as compared to thrombolysis. However, despite optimal epicardial re-
canalization, suboptimal reperfusion and therefore larger infarct size
is observed in a relatively large proportion of patients, especially inTable 1
Baseline demographic and clinical characteristics according to time-to-treatment.
Ischemia time (hours)
Variable b2 (n=106) 2–3 (n=228) 3–4 (n=212)
Age (years) 62.4±11.1 62.6±11.2 63.5±12.6
Female gender (%) 18.9 18.0 23.6
Smoking (%) 52.8 52.6 46.7
Diabetes (%) 10.4 13.2 14.2
Hypertension (%) 53.8 37.7 43.9
Dyslipidemia (%) 37.7 41.2 35.5
Preinfarction angina (%) 7.3 7.1 7.9
Previous MI (%) 3.8 3.9 5.2
Previous CABG (%) 0 0.4 1.9
Previous PTCA (%) 3.8 5.3 2.8
Cardiogenic shock (%) 6.6 1.8 6.6
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spite the demonstrated prognostic role of time to therapy and its lin-
ear association with outcome in patients with STEMI treated by
thrombolysis [14,15], there is still doubt with regard to its role in pa-
tients treated with primary angioplasty [16–21].
Brodie et al. [16] observed a better outcome among patients un-
dergoing primary angioplasty within 2 h from symptom onset,
whereas a relatively stable mortality rate was observed between 2
and 12 h. Consistent with these data, Zijlstra et al. [15], in a recent
pooled-analysis of several randomized trials comparing primary an-
gioplasty and thrombolysis, found a direct relationship between
time from symptom onset to treatment only in patients treated by
thrombolysis, but not by primary angioplasty. Consisting with these
data, the Munich group has shown a significant impact of time-to-
treatment on infarct size only with thrombolysis but not with prima-
ry angioplasty [27]. However, the same group has subsequently ob-
served a significant impact of preprocedural TIMI 3 flow (surrogate
marker of ischemic time) on scintigraphic infarct size [28]. In fact, a
similar impact of preprocedural TIMI flow was observed also in
other studies [29–31].
Conversely, several additional reports have shown the impact if is-
chemia time on mortality. Cannon et al. [18] in a cohort of 27,080 pa-
tients undergoing primary angioplasty found door-to-balloon time to
be associated with mortality. These findings were confirmed by
Antoniucci et al. [19] in high-risk patients. The Zwolle group analyzed
the impact of time-to-treatment as a continuous function in a popula-
tion of 1791 STEMI patients [20]. After correction for baseline con-
founding factors, they observed that every 30 min of delay to
treatment was associated with 7.5% increase in the relative risk of
1-year mortality. In another analysis confined to patients undergoing
transferring for primary angioplasty, De Luca et al. [32] found that
interhospital delay was significantly associated with mortality.
In the DANAMI-2 trial, Maeng et al. [33] found that time-to-
treatment significantly affected predischarge ejection fraction and
3-year mortality. Data from a recent updated meta-analysis of trials
comparing primary angioplasty vs. thrombolysis [34], have shown
similar impact of time-to-treatment for both reperfusion strategies.
Several additional studies have been conducted to contribute to ex-
plain the prognostic role of ischemia time in primary angioplasty.
De Luca et al. [35] showed in a population of 1072 STEMI patients
that time-to-treatment had a significant impact on myocardial perfu-
sion (as evaluated by myocardial blush and ST-segment resolution),
enzymatic infarct size and predischarge ejection fraction. Interesting-
ly, these results were confirmed in the analysis restricted to patients
with postprocedural TIMI 3 flow. Thus, even though primary angio-
plasty is able to restore TIMI 3 flow independently from the time of
treatment, this cannot abrogate the deleterious effects of ischemia
time on myocardial necrosis and perfusion. More recently, data
from the EMERALD trial [36] have shown a clear relationship between
time-to-treatment, myocardial perfusion and infarct size analyzed by4–5 (n=126) 5–6 (n=72) >6 (n=77) p Value trend
65.6±11.7 65.8±12.5 66.2±13.1 b0.001
19.8 25 24.7 0.16
37.3 47.2 50.6 0.16
20.6 9.7 13 0.51
46.8 45.8 37.7 0.48
26.2 31.9 19.5 b0.001
2.9 8.8 15.8 0.65
4.8 1.4 2.6 0.51
0.8 1.4 0 0.7
2.4 0 3.9 0.19
3.2 2.8 2.6 0.095
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Table 2
Angiographic and procedural characteristics according to time-to-treatment.
Ischemia time (hours)
Variable b2 (n=106) 2–3 (n=228) 3–4 (n=212) 4–5 (n=126) 5–6 (n=72) >6 (n=77) p Value trend
Chronic occlusion (%) 3.6 4.3 7.7 5.8 2.9 0 0.795
Collateral circulation 0.22
RENTROP 0 (%) 96.4 88.9 88.7 87.0 85.7 90.0
RENTROP 1 (%) 1.8 7.7 8.3 8.7 8.6 5.0
RENTROP 2 (%) 1.8 2.6 2.3 4.3 5.7 0
RENTROP 3 (%) 0 0.9 0.8 0 0 0
Pre-procedural TIMI flow 0.31
TIMI 0–1 (%) 80.3 80.5 84.1 77.2 88.0 82.1
TIMI 2 (%) 12.8 9.8 7.3 13.2 7.2 13.7
TIMI 3 (%) 6.8 9.8 8.6 9.6 4.8 4.2
Infarct-related artery 0.92
RCA (%) 41.0 45.2 46.8 47.1 48.2 44.8
CX (%) 15.7 14.5 11.1 17.6 15.7 11.5
Graft (%) 0 0 0.4 0 0 0
LAD (%) 43.6 40.3 41.3 35.3 36.1 43.8
LM (%) 0 0 0.7 0 0 0
Multivessel disease (%) 40.0 37.9 43.0 44.1 42.0 41.7 0.428
N. lesions 0.27
1 (%) 76.9 79.8 77.9 72.8 80.7 69.8
2 (%) 17.1 15 18.7 22.8 14.5 21.9
3 (%) 5.1 4.0 3.0 3.7 3.6 7.3
Abciximab (%) 98.3 91.1 87.2 86.8 85.5 94.8 0.13
Stenting (%) 98.2 99.1 99.2 98.5 97.1 100 0.95
Thrombectomy (%) 39.6 43.8 40.5 39.7 47.2 46.7 0.6
IABP (%) 4.3 2.8 5.5 1.5 4.8 7.3 0.21
Post-procedural TIMI 3 flow (%) 95.7 93.9 95.7 86.7 85.5 80.0 b0.001
3G. De Luca et al. / International Journal of Cardiology xxx (2012) xxx–xxxscintigraphy. Similar finding has been observed in a pooled analysis of
4 trials performed by Stone et al. [37], even though the impact was
mostly observed within the first hours. A recent study conducted by
Tarantini et al. [38] has evaluated the impact of time-to-treatment
on infarct size, estimated by MRI. Supporting data by De Luca et al.10
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Fig. 1. Bar graph shows the significant relationship between ischemia time and scinti-
graphic infarct size in all population (A), that was confirmed in the analysis restricted
to patients with postprocedural TIMI 3 flow (B).
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(2012), doi:10.1016/j.ijcard.2012.04.078[20], they observed a significant increase in infarct size by every
30 min delay to treatment.
In our study, including 830 STEMI patients undergoing primary an-
gioplasty, we found that infarct size, accurately assessed bymyocardi-
al perfusion scintigraphy, was linearly related to time-to-treatment.
The relationship was observed even when restricted to patients with
postprocedural TIMI 3 flow. In fact, the impact of time-to-treatment30
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Fig. 2. Bar graph shows the significant relationship between ischemia time and scinti-
graphic infarct size (as above the median) in all population (A), that was confirmed in
the analysis restricted to patients with postprocedural TIMI 3 flow (B).
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Fig. 3. Impact of ischemia time (in minutes on X-axis) on infarct size (as % of left ven-
tricle (LV) on Y-axis). R2-values and P-values refer to the linear correlations.
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as age, dyslipidemia and postprocedural TIMI 3 flow.
All these data support the need to shorten ischemia time by early
diagnosis and direct transportation to the cath lab. The experience in
Zwolle showed that interhospital delay was an independent predictor
of mortality [32]. Similarly, the Danish experience strongly demon-
strated the importance and clinical impact on long-term mortality
[39] and occurrence of heart failure [40] of health care organization
and system delays. Several trials and meta-analysis have evaluated
the role of pharmacological facilitation. Studies on facilitation with
lythic therapy showed a significant increase in the risk of major
bleeding complications and reinfarction [41,42], and therefore this
strategy has been abandoned, whereas great attention has been
paid to Gp IIb–IIIa inhibitors. A previous meta-analysis based on indi-
vidual patients' data [10] showed that early abciximab, but not
Eptifibatide and Tirofiban, was associated with significant benefits
in mortality. These beneficial effects have been confirmed at long-Preprocedural TIMI 0-2 
Preprocedural TIMI 3 
Age < 75 
Age >  75 
Female Sex 
Male Sex 
Non diabetes 
Diabetes 
Non anterior MI 
Anterior MI 
SVD 
MVD 
TTT > 3 hours better TTT >
OR [95% CI]
0.1 0.2 0.5 1 2 
Fig. 4. Impact of ischemia time (≥ or b3 h) on infarct size (as % above the median) in subgro
ease; MVD = multivessel disease.
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tirofiban and double bolus of eptifibatide have been shown to provide
more complete and faster inhibition of platelet aggregation and
therefore larger benefits would be expected from these new dosages.
The on-time-2 trial [44] investigated the benefits from early high-
dose tirofiban administration in the ambulance as compared to place-
bo, with significant benefits in preprocedural recanalization and ST-
resolution. When the data were pooled with the pilot phase, there
was a significant reduction in mortality. These beneficial effects
have been confirmed in large registries [45]. Therefore despite the
negative results of the largest randomized trials (FINESSE) [46], based
on the demonstrated prognostic role of ischemia time, and the current
evidence from randomized and registry data, early administration of
Gp IIb–IIIa inhibitors may be considered, especially among high-risk
patients.
5. Study limitations
We assessed the infarct size 1 month after the index infarction in-
stead of at hospital discharge, as in the majority of previously publi-
shed studies. On the other hand, this circumstance should be more
effective in preventing interference of myocardial stunning with the
extent of perfusion defects [47]. We did not performed routinely in
all patients with coronary angiographic control before gated SPECT
to allow the exclusion of infarct-related vessel restenosis. A potential
bias of later presentation of patients with bigger infarcts seems un-
likely, since there was no significant difference between study groups
regarding the incidence of cardiogenic shock, anterior infarct location,
resuscitation/intubation, and left bundle branch block at presenta-
tion. Only a minority of patients were treated with thrombectomy,
with similar rates across time intervals. However, confirming the re-
sults of the JETSTENT trial [48], the use of thrombectomy did not af-
fect infarct size (11.9±10% vs. 13.1±11%, p=0.25). Finally, our
data must be interpreted with the concept that ischemia time is just
a piece of the puzzle. In fact, final infarct size is certainly influenced
by aging, preprocedural TIMI flow, IRA location, and periprocedural
factors such as ischemia reperfusion damage, distal atherothrombotic
embolization, and no-reflow. Therefore, despite the relatively low R
square value, we strongly believe that the 0.9% increase in infarct
size per each hour of ischemia time (as estimated by our coefficients) 3 hours worse 
OR [95% CI] P value P heter
5 10 
2.03 [1.03-4.03] 
1.8 [1.31-2.47] 
1.89 [1.39-2.56] 
1.16 [0.54-2.52] 
1.62 [1.12-2.33] 
2.05 [1.31-3.21] 
0.4 
<0.001 
<0.001 
0.7 
0.01 
0.002 
1.91 [0.61-5.98] 
1.54 [1.05-2.26] 0.28 
2.07 [1.36-3.14] <0.001 
1.71 [1.29-2.29] <0.001 
0.26 0.85
0.31
0.75
0.25
0.41
1.95 [1.36-2.82] 
1.48 [0.96-2.34] 
<0.001 
0.076 
0.36
ups of patients.OR = odds ratio; MI = myocardial infarction, SVD = single-vessel dis-
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mentioned aspects and the fact that it is a modifiable variable, also
clinically significant. In fact, the impact of ischemia time on infarct
size is the explanation of the demonstrated effect of ischemia time
on survival.
6. Conclusions
This study showed that among STEMI patients undergoing prima-
ry angioplasty, time-to-treatment is linearly and independently asso-
ciated with scintigraphic infarct size. Therefore, all the attempts
should be made in order to reduce ischemia time by making aware
patients of heart attack symptoms and of prompt emergency system
activation, direct transportation to the cath lab and potentially early
pharmacological reperfusion.
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